#Germany #AI in Healthcare #Fresenius Medical Care #Bad Homburg #Hemodiafiltration

Fresenius Medical Care at ASN Kidney Week 2025

Fresenius Medical Care is set to make significant contributions at the upcoming American Society of Nephrology (ASN) Kidney Week 2025, scheduled from November 5 to November 9 in Houston. As the global leader in providing products and services for individuals with kidney diseases, Fresenius Medical Care aims to present pivotal research that underscores the real-world advancements in hemodiafiltration (HDF) and the application of artificial intelligence (AI) within nephrology.

Key Research Highlights

Fresenius Medical Care will showcase multiple research abstracts at the Kidney Week, with a particular focus on the proven benefits of hemodiafiltration. Notably, one abstract has been selected for an oral presentation, emphasizing the link between HDF and reduced risks associated with cardiovascular issues and fluid-related hospitalizations.

Frank Maddux, MD, Global Chief Medical Officer at Fresenius Medical Care, expressed enthusiasm for the forthcoming presentations. He stated, "This research highlights our commitment to patient-centered innovation and shows how advanced therapies like hemodiafiltration can be tailored to enhance outcomes in real-world settings.” The institution’s research indicates that by employing innovative physical principles in treatment, Fresenius is pioneering efforts to elevate care standards and advance precision medicine worldwide.

Important Presentations

Some of the crucial presentations slated for the ASN Kidney Week include:

• - Hemodiafiltration's Role in Reducing Hospitalizations: A study examining how HDF can lower the incidence of hospitalizations due to cardiovascular and fluid-related complications.
• - Implementation of Online High-Volume HDF in U.S. Dialysis Centers: An overview of the first chronic dialysis unit in the U.S. to adopt high-volume HDF technology, showcasing operational insights.
• - AI-Driven Fall Risk Prediction in Dialysis Patients: This presentation will delve into an AI model designed to predict the likelihood of falls among patients during a 31-day period, potentially revolutionizing patient safety practices.
• - AI Chatbots Supporting Clinician Adoption of HDF: Introduction of a real-time AI chatbot that provides verified clinical information to clinicians adopting HDF in practice.
• - Can AI Create Safe Meal Plans for Dialysis Patients?: An exploration of whether generative AI can effectively plan safe and nutritionally sound diets for patients undergoing hemodialysis.

As Maddux pointed out, the exciting aspect of the research is its translation into practice that benefits patients. It combines real-world evidence with the latest technological innovations to help define the future of kidney care and set new benchmarks for nephrology standards.

Events at ASN Kidney Week

In addition to its scientific presentations, Fresenius Medical Care will host a variety of events designed to enhance attendees' understanding of HDF and its implementation:

• - Breakfast Symposium: Titled, “HighVolumeHDF The Next Standard of Care for U.S. Patients – Evidence and Practical Use,” this event will provide participants with insights into the best practices of HDF (Scheduled for November 6).
• - Educational Symposium: On November 7, attendees can participate in a session titled “Hemodiafiltration Considerations for Incorporation into Dialysis Care,” backed by an educational grant from Fresenius Medical Care.
• - Renal Research Institute Annual Symposium: On November 4, the RRI will present “Reimagining Frontline Care: The Power of Research, AI, and Innovation,” focusing on practical applications of AI and technology in kidney treatment.

Attendees can visit Fresenius Medical Care at Booth #1815 to learn more about their research findings, ongoing clinical collaborations, and innovative solutions in the field of kidney care. Additionally, representatives from the Renal Research Institute will be stationed at Booth #1838.

To learn more about Fresenius Medical Care’s engagement at ASN, please visit their website.

About Fresenius Medical Care

Fresenius Medical Care is recognized as the world’s premier provider of products and services for individuals with renal diseases, delivering care to approximately 4.2 million patients globally who require regular dialysis treatment. Through a network comprising 3,676 dialysis clinics, the company administers treatment to around 300,000 patients each day, pioneering the development of dialysis equipment, including machines and dialyzers. Fresenius Medical Care is publicly traded on both the Frankfurt Stock Exchange (Ticker: FME) and the New York Stock Exchange (Ticker: FMS).

For further details, visit their official site at Fresenius Medical Care.

_Note: This article may contain forward-looking statements that intend to convey the expected future performance of Fresenius Medical Care. However, various risks and uncertainties could result in actual outcomes differing from the anticipated ones, reflecting shifts in business conditions, legal regulations, and other unpredictable factors._